NCT01418092已完成2 期
A Phase 2b Randomized, Double-blind, Placebo-controlled, 12-week Study to Evaluate the Safety and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 91
- 试验地点
- 1
- 主要终点
- Change from baseline in the weekly average of complete spontaneous bowel movements during treatment
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of ALKS 37 when administered daily to adults with OIC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are at least 18 years of age at time of consent
- •Have a body mass index (BMI)of 19 to 35 kg/m2 at screening
- •Are receiving prescribed opioid medication for the management of chronic, non-cancer pain
- •Meet the criteria of OIC
- •Agree to use an acceptable method of contraception for the duration of the study
排除标准
- •Pregnancy and/or currently breastfeeding
- •Clinically significant medical condition or illness (other than the condition for which the pain medication is being prescribed)
- •Receiving treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction
- •Any gastrointestinal (GI) disorder (other than opioid-induced constipation) or GI structural abnormality known to affect bowel transit, produce GI obstruction, or contribute to bowel dysfunction
- •Use of naloxone, Subutex or Suboxone, Revia, Vivitrol, Relistor, or Entereg starting 15 days before the first study visit following screening until the end of the study
- •Participation in a clinical trial of a pharmacological agent within 30 days before screening
研究组 & 干预措施
Placebo
Placebo Comparator
Capsules for oral administration
干预措施: Placebo (Drug)
ALKS 37
Experimental
Capsules for oral administration
干预措施: ALKS 37 (Drug)
结局指标
主要结局
Change from baseline in the weekly average of complete spontaneous bowel movements during treatment
时间窗: Weeks 1 through 4 of treatment
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)Opioid-induced ConstipationNCT01382797Alkermes, Inc.157
已完成
2 期
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderAlcohol Use DisorderSchizophreniaNCT02161718Alkermes, Inc.300
已完成
2 期
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)Major Depressive DisorderNCT01500200Alkermes, Inc.142
已完成
2 期
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular EdemaDiabetic Macular Edema (DME)NCT02050828Aerpio Therapeutics144
已完成
1 期
A Study of ALKS 9072 in Subjects With Chronic Stable SchizophreniaSchizophreniaNCT01493726Alkermes, Inc.88